Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BI 1206

Next Previous
Drug Profile

BI 1206

Alternative Names: 6G 11; BI-1206

Latest Information Update: 30 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioInvent International
  • Developer BioInvent International; CASI Pharmaceuticals; Merck Sharp & Dohme; University of Southampton
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Fc gamma receptor IIB antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; Follicular lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Solid tumours
  • No development reported Mantle-cell lymphoma

Most Recent Events

  • 12 May 2025 Kaixin Pharmaceuticals acquires BI 1206 from CASI Pharmaceuticals
  • 08 Jan 2025 Efficacy and adverse event data from a phase I/IIa trial in Non-Hodgkin's lymphoma released by BioInvent International
  • 13 Jun 2024 Efficacy and adverse events data from phase I/II clinical trials in Non-Hodgkin's lymphoma presented at the 29th Congress of the European Haematology Association (EHA-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top